IFCT ONCOBRAF 研究 🇫🇷 #ESMO26：Encorafenib + Binimetinib 在 #BRAF V600mut NSCLC 患者中的 1L 和 2L 治疗中均表现出相当的疗效（mPFS：11.1 和 9.2 个月），生存期延长至 41.1（1L）和 37.5 个月（2L），证实这一联合方案已成为标准治疗。欢迎前来了解更多并与 @C_Ricordel 交流
11 浏览 · 0 赞 · 0 转发 · 0 回复
STARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
https://esmocongress.esmo.orgEncorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: Results from the ECLYPse phase II trial
https://esmocongress.esmo.org- **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
https://esmocongress.esmo.org- **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
https://esmocongress.esmo.org来源：d.planchard · x.com